A
1.57
-0.07 (-4.27%)
| Penutupan Terdahulu | 1.64 |
| Buka | 1.63 |
| Jumlah Dagangan | 265,877 |
| Purata Dagangan (3B) | 495,527 |
| Modal Pasaran | 31,957,352 |
| Harga / Buku (P/B) | 3.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 - 12 May 2025 |
| EPS Cair (TTM) | -2.31 |
| Nisbah Semasa (MRQ) | 3.59 |
| Aliran Tunai Operasi (OCF TTM) | -21.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.17 M |
| Pulangan Atas Aset (ROA TTM) | -138.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -3,159.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Annovis Bio, Inc. | Menurun | Menurun |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.45% |
| % Dimiliki oleh Institusi | 13.40% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Quest Partners Llc | 30 Sep 2024 | 46,002 |
| Sterling Investment Advisors, Ltd. | 31 Dec 2024 | 23,974 |
| Julat 52 Minggu | ||
| Median | 17.00 (982.80%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 15 May 2025 | 17.00 (982.80%) | Beli | 1.69 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 May 2025 | Pengumuman | Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results |
| 29 Apr 2025 | Pengumuman | Annovis Bio Appoints Hui Liu as Director of Biostatistics |
| 27 Mar 2025 | Pengumuman | Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE |
| 25 Mar 2025 | Pengumuman | Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program |
| 21 Mar 2025 | Pengumuman | Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results |
| 11 Mar 2025 | Pengumuman | Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |